Two longtime Healthways analysts on Friday cut their price targets for the population health management play after new and interim CEO Alfred Lumsdaine said 2015 profits will not meet expectations. But both Brooks O'Neil at Dougherty and Sean Wieland at Piper Jaffray are not telling investors to stop buying the company's shares, keeping Healthways at 'buy' and 'overweight' ratings, respectively. O'Neil's target for Healthways, which on Friday fell 20 percent to $12.40 (Ticker: HWAY), has come all the way down to $15 from $25. Wieland is staying more upbeat: His target now stands at $25.50, down from $27.
The skies are decidedly brighter for shareholders of Acadia Healthcare, which has climbed about 25 percent so far in 2015 after rising by about a third last year. Mizuho Securities analysts see even better days ahead and have launched coverage of the Franklin-based company with an 'outperform' rating at a price target of $84. Acadia (Ticker: ACHC) closed Friday trading at $76.47.
Analyst Steve Manaker at Oppenheimer has launched coverage of newly public Community Healthcare Trust with an 'outperform' rating and a price target of $21. A key in his analysis is the type of properties CEO Tim Wallace and his team are targeting: "The key for us is not just management's ability to underwrite the real estate but also the importance of a tenant's place in the local healthcare ecosystem." Community Healthcare Trust (Ticker: CHCT) is changing hands this morning at about $19.10.
Manaker's colleague Mohan Naidu has begun covering shares of population health management company Healthways (Ticker: HWAY) with a neutral rating. Among his concerns are how the exit of former CEO Ben Leedle might hurt contract renewals and the long-term impact of health insurance exchanges on Healthways' work with large employers.
POSTDATA: WARRANTY DEEDS